CLEC1B Expression and PD-L1 Expression Predict Clinical Outcome in Hepatocellular Carcinoma with Tumor Hemorrhage
Authors:
Open Access
- 1 April 2018
- journal article
- research article
- Published by Elsevier in Translational Oncology
- Vol. 11 (2) , 552-558
Abstract
No abstract availableKeywords
Funding Information
- National Nature Science Foundation of China (81372630, 81372631)
This publication has 29 references indexed in Scilit:
- TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune CellsCancer Research, 2017
- Cancer immunotherapies targeting the PD-1 signaling pathwayJournal of Biomedical Science, 2017
- CXCL12 expression and PD-L1 expression serve as prognostic biomarkers in HCC and are induced by hypoxiaVirchows Archiv, 2016
- Increased programmed death ligand-1 expression predicts poor prognosis in hepatocellular carcinoma patientsOncoTargets and Therapy, 2016
- Moving towards personalised therapy in patients with hepatocellular carcinoma: the role of the microenvironmentGut, 2014
- Extravascular Red Blood Cells and Hemoglobin Promote Tumor Growth and Therapeutic Resistance as Endogenous Danger SignalsThe Journal of Immunology, 2014
- Role of the Microenvironment in the Pathogenesis and Treatment of Hepatocellular CarcinomaGastroenterology, 2013
- Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and ElaborationPLOS Medicine, 2012
- CLEC-2 is an essential platelet-activating receptor in hemostasis and thrombosisBlood, 2009
- Involvement of the Snake Toxin Receptor CLEC-2, in Podoplanin-mediated Platelet Activation, by Cancer CellsJournal of Biological Chemistry, 2007